<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00103116</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000410830</org_study_id>
    <secondary_id>R21CA091624</secondary_id>
    <secondary_id>UKMC-IRB-0391-F2R</secondary_id>
    <secondary_id>UKMC-CTRF-G-01-009</secondary_id>
    <nct_id>NCT00103116</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer</brief_title>
  <official_title>Autologous Dendritic Cell Vaccines in Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edward Hirschowitz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's white blood cells and allogeneic tumor cells may
      make the body build an effective immune response to kill tumor cells.

      PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients
      with stage I, stage II, or stage III non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the immunologic effects of adjuvant vaccine therapy comprising autologous
           dendritic cells loaded with allogeneic non-small cell lung cancer (NSCLC) cells in
           patients with unresectable stage IIIA or IIIB, or resected stage I-IIIB NSCLC.

        -  Determine the potential clinical efficacy of this vaccine in these patients.

      OUTLINE: This is an open-label study. Patients are stratified according to type of prior
      primary therapy (surgical vs nonsurgical).

      Patients undergo leukapheresis over 3-4 hours to harvest mononuclear cells for the production
      of dendritic cells (DC). DC are then pulsed with allogeneic non-small cell lung cancer cells
      to produce an autologous dendritic cell vaccine. Patients receive vaccine intradermally once
      a month for 2 months in the absence of disease recurrence or unacceptable toxicity.

      Patients are followed monthly for 4 months, every 6 months for 2 years, and then periodically
      thereafter.

      PROJECTED ACCRUAL: A total of 60 patients (30 per stratum) will be accrued for this study
      within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Showing Immunologic Response to Vaccine Within Six Months of Immunization</measure>
    <time_frame>six months post vaccine</time_frame>
    <description>Antigen specific reaction is measured serially in blood of each participant prior to and through six months post-vaccine. Increase in levels of specific T cell activity from pre vaccine to post vaccine serve as primary measures of an individual's response to vaccine. The number (relative percent) of participants achieving immunologic response to vaccine within 6 month of immunization was the dominant metric of vaccine activity within the study population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Alive Five Years Post Vaccine</measure>
    <time_frame>five years post vaccine</time_frame>
    <description>Documentation of radiographic surveillance for recurrence or progression for 5 years post-vaccine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Autologous dendritic cell cancer vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label nonrandomized</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous dendritic cell cancer vaccine</intervention_name>
    <description>Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure.
Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part.</description>
    <arm_group_label>Autologous dendritic cell cancer vaccine</arm_group_label>
    <other_name>DC vaccine</other_name>
    <other_name>autologous DC vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed non-small cell lung cancer (NSCLC)

               -  Meets 1 of the following stage criteria:

                    -  Completely resected stage I-IIIB disease

                         -  Underwent surgical resection &gt; 4 weeks but ≤ 4 years ago

                    -  Unresectable stage IIIA or IIIB disease AND previously treated with
                       definitive radiotherapy or chemotherapy &gt; 6 weeks ago

               -  Bronchoalveolar carcinomas allowed

          -  Clinically stable disease by chest x-ray or CT scan within the past 6 weeks

               -  No progressive disease

          -  No malignant pleural or pericardial effusions

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 80

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Hemoglobin ≥ 9.0 g/dL

        Hepatic

          -  Bilirubin ≤ 2.5 times upper limit of normal (ULN)

          -  AST and ALT ≤ 2.5 times ULN

          -  No known history of infectious hepatitis

        Renal

          -  Creatinine ≤ 3 mg/dL

          -  Ionized calcium ≥ 0.9 mmol/L (may be replaced)

        Cardiovascular

          -  No known New York Heart Association class III-IV congestive heart failure

          -  No hemodynamically significant valvular heart disease

          -  No myocardial infarction within the past 6 months

          -  No active angina pectoris

          -  No uncontrolled ventricular arrhythmia

          -  No stroke within the past year

          -  No known cerebrovascular disease

          -  No other significant cardiac disease by echocardiogram, stress test, or risk
             assessment by cardiologist (for patients suspected of cardiac disease by history or
             physical exam)

        Immunologic

          -  No known HIV positivity

          -  No other immunosuppressive disorders, including chronic disorders

        Other

          -  Not pregnant

          -  Negative pregnancy test

          -  Potassium ≥ 3.0 mEq/L (may be replaced)

          -  Able to tolerate modest blood volume and electrolyte shifts during leukapheresis

          -  No other malignancy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Prior biologic therapy allowed

          -  Other concurrent biologic therapy allowed

        Chemotherapy

          -  See Disease Characteristics

          -  No concurrent chemotherapy

        Endocrine therapy

          -  No concurrent steroids during and for 16 weeks after study treatment

        Radiotherapy

          -  See Disease Characteristics

          -  No concurrent radiotherapy

        Surgery

          -  See Disease Characteristics

        Other

          -  Prior neoadjuvant or adjuvant therapy for surgically resected patients allowed

          -  No concurrent shorter courses of immunosuppressive medications during and for 16 weeks
             after study treatment

          -  No concurrent chronic immunosuppressive medications

          -  Concurrent cyclooxygenase-2 inhibitors allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Hirschowitz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Lucille P. Markey Cancer Center at University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Markey Cancer Center at University of Kentucky Chandler Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0293</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer. 2007 Sep;57(3):365-72. Epub 2007 May 16.</citation>
    <PMID>17509725</PMID>
  </results_reference>
  <results_reference>
    <citation>Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol. 2004 Jul 15;22(14):2808-15.</citation>
    <PMID>15254048</PMID>
  </results_reference>
  <results_reference>
    <citation>Hirschowitz EA, Yannelli JR. Immunotherapy for lung cancer. Proc Am Thorac Soc. 2009 Apr 15;6(2):224-32. doi: 10.1513/pats.200806-048LC. Review.</citation>
    <PMID>19349492</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2005</study_first_submitted>
  <study_first_submitted_qc>February 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2005</study_first_posted>
  <results_first_submitted>November 7, 2013</results_first_submitted>
  <results_first_submitted_qc>March 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2017</results_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Edward Hirschowitz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Non-randomized open label; stage I-IIIB NSCLC. Closed to accrual in 2006 when defined phase I immunological endpoints were reached.</recruitment_details>
      <pre_assignment_details>None excluded; all completed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vaccine</title>
          <description>therapeutic autologous dendritic cells : Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure. Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vaccine</title>
          <description>therapeutic autologous dendritic cells : Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure. Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Showing Immunologic Response to Vaccine Within Six Months of Immunization</title>
        <description>Antigen specific reaction is measured serially in blood of each participant prior to and through six months post-vaccine. Increase in levels of specific T cell activity from pre vaccine to post vaccine serve as primary measures of an individual's response to vaccine. The number (relative percent) of participants achieving immunologic response to vaccine within 6 month of immunization was the dominant metric of vaccine activity within the study population.</description>
        <time_frame>six months post vaccine</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>therapeutic autologous dendritic cells : Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure. Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Showing Immunologic Response to Vaccine Within Six Months of Immunization</title>
          <description>Antigen specific reaction is measured serially in blood of each participant prior to and through six months post-vaccine. Increase in levels of specific T cell activity from pre vaccine to post vaccine serve as primary measures of an individual's response to vaccine. The number (relative percent) of participants achieving immunologic response to vaccine within 6 month of immunization was the dominant metric of vaccine activity within the study population.</description>
          <units>participants with immunological response</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Alive Five Years Post Vaccine</title>
        <description>Documentation of radiographic surveillance for recurrence or progression for 5 years post-vaccine</description>
        <time_frame>five years post vaccine</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>therapeutic autologous dendritic cells : Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure. Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Alive Five Years Post Vaccine</title>
          <description>Documentation of radiographic surveillance for recurrence or progression for 5 years post-vaccine</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>five years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vaccine</title>
          <description>therapeutic autologous dendritic cells : Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure. Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>injection site reaction</sub_title>
                <description>Self limited injection site reaction was observed in half the study participants</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edward Hirschowitz</name_or_title>
      <organization>UKentucky</organization>
      <phone>8596081981</phone>
      <email>eahirs2@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

